EGF-REpidermal Growth Factor Receptor
References in periodicals archive ?
At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted sales of more than US$ 2.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases.
Several antibodies targeting EGF-R and small molecules inhibiting the EGF-R tyrosine kinase have been approved and are used for treatment of colorectal cancer, squamous cell cancer of the head & neck or pancreatic cancer, respectively.
Competitor Analysis: EGF-R Agonists and Antagonists" includes a compilation of current active projects in research and development of molecules targeting the EGF receptor.
Apart from the economic attractiveness, it is also the validated target of therapeutic antibodies which attracts technology companies to create and develop improved versions of established therapeutic antibodies against CD20, Her2, VEGF, TNF, EGF-R and TNF.
The pipeline of novel EGF-R targeting molecules is rather full and includes novel antibody as well as vaccine approaches and small molecules with a broader inhibition profile.
In addition, the report lists company-specific R&D pipelines of EGF-R targeting small molecules, antibodies, proteins, cells and vaccines.
A drug candidate, SU5271, has been selected that is a potent inhibitor of EGF-R signalling, and a license has been signed with Zeneca Ltd.
Psoriatic lesions are caused by the hyperproliferation of keratinocytes, and work by SUGEN and others has demonstrated that EGF-R signalling is required for the growth of keratinocytes.